Literature DB >> 984799

Pharmacokinetics of cefamandole in the presence of renal failure in patients undergoing hemodialysis.

G B Appel, H C Neu, M F Parry, M J Goldberger, G B Jacob.   

Abstract

The pharmacology of cefamandole in seven patients with stable renal insufficiency and in eight patients undergoing hemodialysis was determined. All patients had creatinine clearances less than 5 ml/min. The half-life of cefamandole in those patients with stable chronic renal failure was 7.7 +/- 2.2 h. The mean venous level 1 h after intravenous injection of a 1-g dose was 85.3 +/- 32.0 mug/ml. The mean venous half-life of cefamandole during hemodialysis was 6.1 h. The venous serum level after 5.5 of hemodialysis was 50.4 +/- 20.8 mug/ml. The mean coefficient of extraction was 0.155, and the mean clearance was 34.7 ml/min. The time interval between doses of cefamandole administered intravenously should be lengthened to 24 h in the presence of stable renal failure. No major change in dosage schedule is necessary for patients undergoing dialysis.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 984799      PMCID: PMC429804          DOI: 10.1128/AAC.10.4.623

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

Review 1.  Drug therapy: The newer cephalosporins.

Authors:  R C Moellering; M N Swartz
Journal:  N Engl J Med       Date:  1976-01-01       Impact factor: 91.245

Review 2.  Pharmacokinetics and clinical use of cephalosporin antibiotics.

Authors:  C H Nightingale; D S Greene; R Quintiliani
Journal:  J Pharm Sci       Date:  1975-12       Impact factor: 3.534

3.  Pharmacological studies with cefamandole in human volunteers.

Authors:  B R Meyers; B Ribner; S Yancovitz; S Z Hirschman
Journal:  Antimicrob Agents Chemother       Date:  1976-01       Impact factor: 5.191

4.  Clinical pharmacology of cefamandole as compared with cephalothin.

Authors:  I W Fong; E D Ralph; E R Engelking; W M Kirby
Journal:  Antimicrob Agents Chemother       Date:  1976-01       Impact factor: 5.191

5.  Guidelines to antibiotic therapy in renal failure.

Authors:  H C Neu
Journal:  Med Times       Date:  1973-11

6.  Cefamandole, a cephalosporin antibiotic with an unusually wide spectrum of activity.

Authors:  H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1974-08       Impact factor: 5.191

7.  In vitro activity and pharmacokinetics in patients of cefamandole, a new cephalsoporin antibiotic.

Authors:  N K Shemonsky; J Carrizosa; M E Levison
Journal:  Antimicrob Agents Chemother       Date:  1975-12       Impact factor: 5.191

8.  Antibacterial activity of cefamandole, a new cephalosporin antibiotic, compared with that of cephaloridine, cephalothin, and cephalexin.

Authors:  S Eykyn; C Jenkins; A King; I Phillips
Journal:  Antimicrob Agents Chemother       Date:  1973-06       Impact factor: 5.191

  8 in total
  4 in total

1.  Therapy of serious infections with cefamandole.

Authors:  M F Parry; M J Goldberger; H C Neu
Journal:  Infection       Date:  1978       Impact factor: 3.553

Review 2.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

3.  Disposition kinetics of cefamandole during continuous ambulatory peritoneal dialysis.

Authors:  M Bliss; M Mayersohn; T Arnold; J Logan; U F Michael; W Jones
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

4.  Differences in kinetic properties of drugs: implications as to the selection of a particular drug for use in patients with renal failure with special emphasis on antibiotics and beta-adrenoceptor blocking agents.

Authors:  J Fabre; H M Fox; P Dayer; L Balant
Journal:  Clin Pharmacokinet       Date:  1980 Sep-Oct       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.